Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,issuanceOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,epsCurrentYear,market,shortName,exchange,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,exchangeDataDelayedBy,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,ICPT,-199998000,33162100,50766000,,-40420000,,-40420000,59271000,80851000,-29186000,-29186000,,-12419000,,,,0,81661000,110847000,810000,-11234000,,-40420000,-40420000,2241273000,720109000,-199998000,9542000,520111000,33000,7433000,-2438766000,-2538000,15900000,92946000,146233000,-2538000,16648000,487563000,318237000,43894000,568114000,12583000,91717000.0,-29286000.0,91340000.0,-1083000.0,-3370000.0,34725000.0,-1083000.0,-882000.0,-54650000.0,870000.0,86000.0,-1408000.0,11346000.0,-377000.0,,341330000,en-US,US,EQUITY,True,Delayed Quote,15.05,1630526403,0.14000034,15.0,15.1,14.69,953024,-3.6707318,-6.032,15.780571,-0.7305708,-0.046295587,19.687464,-4.6374636,-0.23555414,499089600,-3.0465586,-2.4950266,15,America/New_York,EDT,False,False,USD,-4.1,us_market,"Intercept Pharmaceuticals, Inc.",NMS,PRE,2,0.9389695,14.69 - 15.1,14.91,0.0,0.0,10,9,finmb_11382658,NasdaqGS,"Intercept Pharmaceuticals, Inc.",USD,846384,1017400,3.4499998,0.29741377,11.6 - 47.46,-32.41,-0.6828909,11.6,47.46,1620304200,1636378200,0,1636723800,-6.714,-4.94,-14400000,1.53,,,47.46,11.6,15.78,19.69,846.38k,1.02M,33.16M,,28.21M,15.36%,76.37%,5.71M,5.65,23.75%,17.22%,6.25M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-69.11%,-50.47%,-17.16%,,321.7M,9.72,12.40%,307.37M,-159.13M,-222.32M,-6.71,,411.18M,12.4,581.22M,,3.33,-6.03,-125.94M,-48.29M,Value,10001,Healthcare,498,5,2,"Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.",New York,646 747 1000,NY,6,1609372800,1625011200,5,United States,http://www.interceptpharma.com,86400,5,10 Hudson Yards,Biotechnology,37th floor
t-1,ICPT,-166853000,33162100,51898000,,-52147000,,-52147000,69956000,82501000,-39353000,-39353000,,-12253000,,,,0,83268000,122621000,767000,-12794000,,-52147000,-52147000,2233937000,747342000,-166853000,11446000,580489000,33000,7503000,-2398346000,-2477000,16095000,58151000,179076000,-2477000,18653000,545741000,411516000,44049000,560582000,24594000,31745000.0,9602000.0,29844000.0,-156000.0,986000.0,14163000.0,-157000.0,450000.0,-15975000.0,836000.0,-159000.0,-1825000.0,19366000.0,-1901000.0,1000.0,366665000,en-US,US,EQUITY,True,Delayed Quote,15.05,1630526403,0.14000034,15.0,15.1,14.69,953024,-3.6707318,-6.032,15.780571,-0.7305708,-0.046295587,19.687464,-4.6374636,-0.23555414,499089600,-3.0465586,-2.4950266,15,America/New_York,EDT,False,False,USD,-4.1,us_market,"Intercept Pharmaceuticals, Inc.",NMS,PRE,2,0.9389695,14.69 - 15.1,14.91,0.0,0.0,10,9,finmb_11382658,NasdaqGS,"Intercept Pharmaceuticals, Inc.",USD,846384,1017400,3.4499998,0.29741377,11.6 - 47.46,-32.41,-0.6828909,11.6,47.46,1620304200,1636378200,0,1636723800,-6.714,-4.94,-14400000,1.53,,,47.46,11.6,15.78,19.69,846.38k,1.02M,33.16M,,28.21M,15.36%,76.37%,5.71M,5.65,23.75%,17.22%,6.25M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-69.11%,-50.47%,-17.16%,,321.7M,9.72,12.40%,307.37M,-159.13M,-222.32M,-6.71,,411.18M,12.4,581.22M,,3.33,-6.03,-125.94M,-48.29M,Value,10001,Healthcare,498,5,2,"Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.",New York,646 747 1000,NY,6,1609372800,1625011200,5,United States,http://www.interceptpharma.com,86400,5,10 Hudson Yards,Biotechnology,37th floor
t-2,ICPT,-130287000,33162100,48858000,,-66469000,,-66469000,70619000,77695000,-41782000,-41782000,,-12091000,,,,0,79521000,121303000,1826000,-24687000,,-66469000,-66469000,2217625000,721639000,-130287000,18048000,591352000,33000,6180000,-2346199000,-1746000,15308000,45311000,163124000,-1746000,14953000,561091000,445269000,41349000,553216000,15468000,36424000.0,575000.0,35092000.0,-226000.0,-3112000.0,-5446000.0,-226000.0,166000.0,-40478000.0,710000.0,640000.0,1391000.0,18584000.0,-1332000.0,1000.0,397967000,en-US,US,EQUITY,True,Delayed Quote,15.05,1630526403,0.14000034,15.0,15.1,14.69,953024,-3.6707318,-6.032,15.780571,-0.7305708,-0.046295587,19.687464,-4.6374636,-0.23555414,499089600,-3.0465586,-2.4950266,15,America/New_York,EDT,False,False,USD,-4.1,us_market,"Intercept Pharmaceuticals, Inc.",NMS,PRE,2,0.9389695,14.69 - 15.1,14.91,0.0,0.0,10,9,finmb_11382658,NasdaqGS,"Intercept Pharmaceuticals, Inc.",USD,846384,1017400,3.4499998,0.29741377,11.6 - 47.46,-32.41,-0.6828909,11.6,47.46,1620304200,1636378200,0,1636723800,-6.714,-4.94,-14400000,1.53,,,47.46,11.6,15.78,19.69,846.38k,1.02M,33.16M,,28.21M,15.36%,76.37%,5.71M,5.65,23.75%,17.22%,6.25M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-69.11%,-50.47%,-17.16%,,321.7M,9.72,12.40%,307.37M,-159.13M,-222.32M,-6.71,,411.18M,12.4,581.22M,,3.33,-6.03,-125.94M,-48.29M,Value,10001,Healthcare,498,5,2,"Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.",New York,646 747 1000,NY,6,1609372800,1625011200,5,United States,http://www.interceptpharma.com,86400,5,10 Hudson Yards,Biotechnology,37th floor
t-3,ICPT,-78796000,33162100,34042000,,-63281000,,-63281000,93360000,75372000,-52030000,-52030000,,-11933000,,,,0,77249000,129279000,1877000,-11251000,,-63281000,-63281000,2202026000,716290000,-78796000,5488000,637494000,33000,6159000,-2279730000,-1125000,15515000,50778000,163536000,-1125000,15327000,606652000,483697000,43276000,546013000,28025000,26290000.0,11585000.0,26064000.0,442000.0,4526000.0,10518000.0,-289000.0,-1146000.0,-14842000.0,808000.0,1627000.0,4337000.0,18511000.0,-226000.0,731000.0,443116000,en-US,US,EQUITY,True,Delayed Quote,15.05,1630526403,0.14000034,15.0,15.1,14.69,953024,-3.6707318,-6.032,15.780571,-0.7305708,-0.046295587,19.687464,-4.6374636,-0.23555414,499089600,-3.0465586,-2.4950266,15,America/New_York,EDT,False,False,USD,-4.1,us_market,"Intercept Pharmaceuticals, Inc.",NMS,PRE,2,0.9389695,14.69 - 15.1,14.91,0.0,0.0,10,9,finmb_11382658,NasdaqGS,"Intercept Pharmaceuticals, Inc.",USD,846384,1017400,3.4499998,0.29741377,11.6 - 47.46,-32.41,-0.6828909,11.6,47.46,1620304200,1636378200,0,1636723800,-6.714,-4.94,-14400000,1.53,,,47.46,11.6,15.78,19.69,846.38k,1.02M,33.16M,,28.21M,15.36%,76.37%,5.71M,5.65,23.75%,17.22%,6.25M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-69.11%,-50.47%,-17.16%,,321.7M,9.72,12.40%,307.37M,-159.13M,-222.32M,-6.71,,411.18M,12.4,581.22M,,3.33,-6.03,-125.94M,-48.29M,Value,10001,Healthcare,498,5,2,"Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.",New York,646 747 1000,NY,6,1609372800,1625011200,5,United States,http://www.interceptpharma.com,86400,5,10 Hudson Yards,Biotechnology,37th floor
